VIM and breast carcinoma: Although current data on the biological role of resistin in breast cancer is very limited, it has been found to promote breast cancer progression via stimulation of proliferation, migration and metastatic behavior of breast cancer cells through interleukin-6, STAT-3 and c-Src activation, along with induction of epithelial-mesenchymal transition and the mesenchymal marker vimentin (38–40).